imatinib mesylate has been researched along with Leukemia, Pre-B-Cell in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 17 (60.71) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Buono, R; Duong, MR; Fruman, DA; Gotesman, M; Herzog, LO; Lee, JS; Mallya, S; Thao, J; Vo, TT | 1 |
| Chen, Y; Huang, P; Long, YY; Luo, X; Shi, L; Su, Q; Yao, SS | 1 |
| Azuma, H; Hatakeyama, N; Imamura, T; Kanayama, T; Kiyokawa, N; Ohki, K; Osumi, T; Sakurai, Y; Sarashina, T; Toriumi, N | 1 |
| Jiao, B; Li, D; Liao, L; Liu, M; Liu, P; Ren, R; Wang, P; Xia, Z; Xiao, X; Zhang, X | 1 |
| Beitzen-Heineke, A; Fiedler, W; Reinert, J; Schwartz, S; Stelljes, M; Wethmar, K | 1 |
| Hasegawa, D; Iijima, K; Ishida, T; Kishimoto, K; Kosaka, Y; Kozaki, A; Matsumoto, H; Mori, T; Nakamachi, Y; Nino, N; Nishimura, N; Saegusa, J; Saito, A; Sakaguchi, K; Shono, A; Tahara, T; Takafuji, S; Tamura, A; Uemura, S; Yamamoto, N; Yokoi, T | 1 |
| Angaroni, F; Barcella, M; Barlassina, C; Buklijas, K; Caccia, M; Casalone, R; Conti, A; D'Avila, F; Maserati, E; Michelato, A; Micheloni, G; Millefanti, G; Pirrone, C; Piscitelli, E; Porta, G; Rainero, A; Sirchia, S; Spinelli, O; Tararà, L; Valli, R | 1 |
| Kivinen, K; Lohi, O; Lund-Aho, T; Lundán, T; Nikkilä, A; Porkka, K; Poukka, M; Raittinen, P | 1 |
| Burki, TK | 1 |
| Islam, R; Krishnan, S; Mishra, DK; Parihar, M; Saha, D; Saha, V; Singh, MK | 1 |
| Avner, S; Carroll, JS; Chalmel, F; Debaize, L; Delalande, O; Dorsheimer, L; Galibert, MD; Gandemer, V; Gaudichon, J; Jakobczyk, H; Rieger, MA; Rio, AG; Salbert, G; Sérandour, AA; Troadec, MB; Zörnig, M | 1 |
| Beldjord, K; Boissel, N; Clappier, E; Dombret, H; Lengline, E; Soulier, J | 1 |
| Berenguer-Potenciano, M; Camacho-Salas, A; Nunez-Enamorado, N; Perez-Alonso, V; Simon-De Las Heras, R; Villora-Morcillo, N | 1 |
| Alperstein, W; Boren, M; McNeer, JL | 1 |
| Chilton, L; Cummins, M; Elliott, A; Goulden, N; Harrison, CJ; Moorman, AV; Moppett, J; Murray, J; Parker, CA; Richardson, S; Ryan, SL; Saha, V; Schwab, C; Tunstall, O; Vora, A; Wragg, C | 1 |
| Moorman, AV | 1 |
| Attarbaschi, A; Haas, OA; König, M; Lackner, H; Mann, G; Panzer-Grümayer, R; Perwein, T; Strehl, S; Urban, EC | 1 |
| Abbenante, MC; Derenzini, E; Ferrari, A; Ghelli Luserna Di Rorà, A; Guadagnuolo, V; Iacobucci, I; Imbrogno, E; Martinelli, G; Paolini, S; Papayannidis, C; Parisi, S; Robustelli, V; Sartor, C | 1 |
| Adachi, T; Aikawa, E; Akiyama, M; Kawauchi, K; Motoji, T; Ozaki, K; Yamada, O | 1 |
| Cornelissen, JJ; Schnog, JB; Van Hest, RM; Van't Veer, MB | 1 |
| Beldjord, K; Béné, MC; Blanchet, O; Bousquet, M; Broccardo, C; Brousset, P; Cavé, H; Cayuela, JM; Chalandon, Y; Coyaud, E; Dastugue, N; De Vos, J; Delabesse, E; Delannoy, A; Dobbelstein, S; Dombret, H; Familiades, J; Grardel, N; Huguet, F; Ifrah, N; Lafage-Pochitaloff, M; Lhéritier, V; Macintyre, EA; Pigneux, A; Prade-Houdellier, N; Preudhomme, C; Quelen, C; Soulier, J; Struski, S | 1 |
| Chavarria-Smith, JE; Huang, D; Kuo, TC; Schlissel, MS | 1 |
| Cantú-Rodríguez, O; García-Rodríguez, F; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, H; Jaime-Pérez, J | 1 |
| Carroll, WL; Chan, LN; Chen, Z; Geng, H; Hurtz, C; Jumaa, H; Lefebvre, V; Melnick, A; Müschen, M; Paietta, E; Ramezani-Rad, P; Willman, CL | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Limnander, A; Niki, M; Oki, S; Pandolfi, PP; Rothman, PB; Yao, PM | 1 |
| Feldhahn, N; Herzog, S; Jumaa, H; Klein, F; Mooster, JL; Müschen, M; Sprangers, M | 1 |
| Angelucci, E; Barbui, T; Bassan, R; Fabris, P; Grassi, A; Guerini, V; Intermesoli, T; Lambertenghi-Deliliers, G; Micò, C; Oldani, E; Peruta, B; Rambaldi, A; Rossi, G; Salvi, A; Spinelli, O; Tosi, M; Zanotti, MC | 1 |
2 review(s) available for imatinib mesylate and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Topics: Child; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators | 2021 |
New and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; B-Lymphocytes; Biomarkers, Tumor; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Gene Expression; Humans; Imatinib Mesylate; Nitriles; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrazoles; Pyrimidines; Survival Analysis; Translocation, Genetic | 2016 |
26 other study(ies) available for imatinib mesylate and Leukemia, Pre-B-Cell
| Article | Year |
|---|---|
Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Topics: Animals; Cell Line, Tumor; Dasatinib; Eukaryotic Initiation Factor-4F; Imatinib Mesylate; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
[BAX Gene Deletion Reduces the Sensitivity of BCR-ABL-Induced B-ALL Cells of Mice to Imatinib].
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Deletion; Imatinib Mesylate; Mice; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2019 |
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Azepines; Benzamides; Cell Line, Tumor; Dasatinib; Drug Screening Assays, Antitumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasm Proteins; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Pyrimidines; Radiation Chimera; Random Allocation; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles | 2020 |
Loss of CD22 expression and expansion of a CD22
Topics: Adult; Aged, 80 and over; Allografts; Antibodies, Bispecific; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clone Cells; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunophenotyping; Inotuzumab Ozogamicin; Lymphocyte Subsets; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Sorafenib; Treatment Failure; Young Adult | 2021 |
ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Topics: Adolescent; Chromosome Deletion; Chromosomes, Human, Pair 7; Dasatinib; ETS Translocation Variant 6 Protein; Female; Gene Fusion; Gene Rearrangement; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, B-Cell; Maintenance Chemotherapy; Oncogene Proteins v-abl; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins | 2018 |
gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.
Topics: Aged; DNA; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Young Adult | 2018 |
Acute Lymphoblastic Leukemia With INPP5D-ABL1 Fusion Responds to Imatinib Treatment.
Topics: Adolescent; Antineoplastic Agents; Down Syndrome; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Oncogene Proteins, Fusion; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl | 2019 |
Intensified treatment for IKZF1-deleted childhood leukaemia.
Topics: Age of Onset; Antineoplastic Agents; Biomarkers, Tumor; Clinical Decision-Making; Clinical Trials as Topic; Gene Deletion; Genetic Predisposition to Disease; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Molecular Targeted Therapy; Patient Selection; Phenotype; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome | 2018 |
A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.
Topics: Adolescent; Child; Child, Preschool; Core Binding Factor Alpha 2 Subunit; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Karyotyping; Male; Oncogene Proteins, Fusion; Ploidies; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Risk Assessment | 2018 |
Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation.
Topics: Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Chromatin; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Enhancer Elements, Genetic; Gene Expression Regulation, Leukemic; HEK293 Cells; Humans; Imatinib Mesylate; Mice; Mice, Inbred NOD; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, B-Lymphoid; Primary Cell Culture; Protein Binding; Proto-Oncogene Proteins c-kit; RNA-Binding Proteins; Signal Transduction; Transcription, Genetic; Xenograft Model Antitumor Assays | 2018 |
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Topics: Adolescent; Benzamides; Humans; Imatinib Mesylate; Male; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators; Treatment Outcome | 2013 |
[Therapeutic response to pyridoxine and pyridostigmine in a paediatric case of severe peripheral and cranial polyneuropathy due to vincristine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blepharoptosis; Cranial Nerve Diseases; Daunorubicin; Diagnosis, Differential; Esotropia; Female; Guillain-Barre Syndrome; Humans; Imatinib Mesylate; Infant; Peripheral Nervous System Diseases; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyridostigmine Bromide; Pyridoxine; Quadriplegia; Vincristine | 2015 |
Pediatric Acute Lymphoblastic Leukemia: From Diagnosis to Prognosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Child, Preschool; Humans; Imatinib Mesylate; Injections, Spinal; Male; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis | 2015 |
EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Chromosomes, Human, Pair 5; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Male; Neoplasm, Residual; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Sequence Deletion; Trans-Activators; Translocation, Genetic; Treatment Outcome; Young Adult | 2016 |
Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Topics: Adolescent; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Male; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-abl; Recurrence; Remission Induction; Salvage Therapy | 2016 |
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Clofarabine; Dasatinib; Drug Synergism; Humans; Imatinib Mesylate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2016 |
Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Telomere; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Drug Interactions; Edema; Etoposide; Female; Humans; Imatinib Mesylate; Leucovorin; Methotrexate; Middle Aged; Piperazines; Pleural Effusion, Malignant; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Sodium Potassium Chloride Symporter Inhibitors; Translocation, Genetic | 2008 |
PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.
Topics: Adolescent; Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Clinical Trials, Phase II as Topic; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Gene Dosage; Gene Rearrangement, T-Lymphocyte; Genomics; Haplotypes; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Immunophenotyping; Middle Aged; Multicenter Studies as Topic; PAX5 Transcription Factor; Piperazines; Point Mutation; Pre-B-Cell Leukemia Transcription Factor 1; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Pyrimidines; Young Adult | 2009 |
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Gene Library; Humans; Imatinib Mesylate; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Transcription, Genetic | 2011 |
Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Philadelphia Chromosome; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Thiazoles; Transplantation, Homologous; Young Adult | 2011 |
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Survival; Child; DNA Methylation; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Radiation Chimera; Randomized Controlled Trials as Topic; Signal Transduction; SOXC Transcription Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.
Topics: Animals; Apoptosis; Benzamides; Bone Marrow Cells; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Gene Expression Regulation, Leukemic; Imatinib Mesylate; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Methionine; Mice; Oncogene Proteins v-abl; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; ras Proteins; RNA-Binding Proteins; Signal Transduction | 2005 |
BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells.
Topics: Alternative Splicing; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Lineage; Cell Nucleus; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Silencing; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Mice; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Gene Deletion; Gene Rearrangement, B-Lymphocyte; Gene Rearrangement, T-Lymphocyte; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Kinetics; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Pyrimidines; Remission Induction; Risk; Survival Analysis; Survival Rate; T-Cell Acute Lymphocytic Leukemia Protein 1; Translocation, Genetic; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2007 |